Hematology & Oncology Doctors in Bellflower, CA Accepting Medicare

6 Hematology & Oncology doctors found. Showing 1 - 6

Dr. Ana Franco Borgas, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9400 Rosecrans Ave, Module 3200, Bellflower, CA 90706 Phone: 562-461-4033    Fax: 562-461-4047

Elizabeth D. Simmons, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000

Everett Hsing-chih Chen, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000

Carole L. Most, MD Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000

Han A. Koh, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000

Dr. Youssef K. Gamal, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9400 Rosecrans Ave Fl 1, Bellflower, CA 90706 Phone: 714-399-0620    Fax: 714-399-0621

News Archive

First Edition: May 10, 2010

Today's health policy headlines include the feature coverage of aspects of health reform implementation, including how "gradfathering" will be defined in regulations and the latest details on the early retiree reinsurance program.

ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention

The international ATOLL study sponsored by the Assistance Publique - Hopitaux de Paris showed that enoxaparin reduced the composite of death, complication of myocardial infraction, procedure failure or major bleeding by 17% in comparison with standard heparin death, recurrent acute coronary syndrome or urgent revascularisation. The results of the ATOLL study were presented at the hotline session of the annual European Cardiology Congress (ESC 2010) in Stockholm, Sweden.

SLU researcher discovers way to block pain pathway

In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health and other academic institutions have discovered a way to block a pain pathway in animal models of chronic neuropathic pain including pain caused by chemotherapeutic agents and bone cancer pain suggesting a promising new approach to pain relief.

Merck sells 50% interest in JJMCP joint venture

Merck, known outside the United States and Canada as MSD, today announced that the company has sold its 50 percent interest in the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. joint venture (JJMCP) to Johnson & Johnson (J&J) affiliates, McNEIL-PPC, Inc., McNEIL MMP, LLC, and Johnson & Johnson, Inc.

Read more Medical News

› Verified 8 days ago